Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
Public ClinicalTrials.gov record NCT02019550. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Study identification
- NCT ID
- NCT02019550
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- EMD Serono
- Industry
- Enrollment
- 97 participants
Conditions and interventions
Conditions
Interventions
- Rebif Rebidose Device
- Rebiject II Device
Device
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2014
- Primary completion
- Dec 31, 2015
- Completion
- Dec 31, 2015
- Last update posted
- Mar 6, 2017
2014 – 2016
United States locations
- U.S. sites
- 21
- U.S. states
- 19
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research site | Cullman | Alabama | 35058 | — |
| Research Site | Tuscon | Arizona | 85718 | — |
| Research Site | Newport Beach | California | 92663 | — |
| Research site | Fort Collins | Colorado | 80528 | — |
| Research Site | Dover | Delaware | 19901 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research site | Sunrise | Florida | 33351 | — |
| Research Site | Atlanta | Georgia | 30327 | — |
| Research Site | Indianapolis | Indiana | 46256 | — |
| Research site | Foxborough | Massachusetts | 02035 | — |
| Research site | Golden Valley | Minnesota | 55422 | — |
| Research Site | Stratford | New Jersey | 08084 | — |
| Research Site | Patchogue | New York | 11772 | — |
| Research Site | Hickory | North Carolina | 28602 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Dayton | Ohio | 45417 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Greensburg | Pennsylvania | 15601 | — |
| Research site | Spartanburg | South Carolina | 29307 | — |
| Research Site | Knoxville | Tennessee | 37934 | — |
| Research site | Mansfield | Texas | 76063 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02019550, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 6, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02019550 live on ClinicalTrials.gov.